You are here

Desert Medical Imaging Chooses CLS Mobile Laser & Non-Cooled Fiber for Clinical Trial of MRI-Guided Focal Laser Therapy for Prostate Cancer

FRAMINGHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS Americas), a subsidiary of CLS AB in Lund, Sweden, today announced its TRANBERG® Thermal Therapy System will be used by Desert Medical Imaging in conjunction with a Phase II clinical trial to study Prostate Ablation in Patients with Localized Prostate Cancer. Other companies' products will also be used in the study.

“We first became familiar with CLS and its non-cooled fiber during an earlier study of ours which was published in a poster at this year’s AUA Annual Meeting,” stated Bernadette M. Greenwood, BSc, PG Cert., RT(R)(MR) and Co-Investigator for the study. “In our experience, their products performed satisfactorily with regards to safety, ease of use, and effectiveness, which is why we will continue to use them during our clinical trial program.”  

“Desert Medical Imaging is a pioneer and visionary in the advanced, minimally invasive treatment of prostate cancer utilizing MRI-guided focal laser ablation therapy,” stated Dan Mogren, Chief Commercial Officer and Clinical Laserthermia Systems. “We are pleased and excited to continue our association with DMI as it demonstrates our relevance and effectiveness in this area compared with other leading products in the field of urology.”

About the Clinical Trial
The purpose of this study is to obtain information on the efficacy of transrectally-delivered MRI guided Laser Focal Therapy using real-time MR thermometry in an outpatient setting. The system is designed to ablate prostate tissue under Magnetic Resonance Imaging (MRI) guidance using laser energy and the procedure is performed in an ambulatory outpatient imaging center under NCT 02234033.

In the United States alone, new prostate cancer cases for 2017 were estimated at 161,360 and deaths at 26,730 according to the AACR. Focal therapies for low risk and intermediate risk localized prostate cancer are increasingly being explored. 

About the CLS TRANBERG Thermal Therapy System
CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories.

The CLS computer controlled mobile laser unit is equipped with touch screen graphical user interface and an integrated tissue temperature control system for use during US/CT guidance. Real-time tissue temperature measurements can be used to control the output power throughout the thermal therapy or ablation procedure. This feature offers superior safety and increases thermal precision.

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund, Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on

The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

CONTACT: Media Contact
TopSpin Communications
Joe Waldygo
P: 480-363-8774

Company Contact
CLS Americas, Inc.
Alan Weinberg, General Manager 
P: 508-620-4521
Tuesday, August 7, 2018 - 07:00